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Abstract 
Study design: This study examines the links between severity of whiplash associated disorder 
and costs and health outcomes 
Objective: The aim of this study was to estimate the economic costs and health state utilities 
associated with disability levels and recovery trajectories following acute whiplash injury. 
Summary of background data: Data used were from the Managing Injuries of the Neck Trial, 
which collected information on 3,851 people over a 12 month period following acute 
whiplash injury. 
Methods: Effects of whiplash associated disorder severity on economic costs (measured from 
a societal perspective and separately from a health and personal social services perspective) 
were estimated using two-part regression models, comprising probability of incurring a cost 
and the total cost, given one was incurred. Effects on health state utilities (measured using the 
EQ-5D and SF-6D) were estimated using ordinary least squares regression, and two-part 
models as for costs. 
Results: There was a direct relationship between severity of disability following acute 
whiplash injury and economic costs. Between baseline and 4 months, average societal costs 
for those with no disability were £99.55 (UK£, 2009 prices), increasing to £668.53 for those 
with complete disability. Average societal costs for the whole sample were £234.15 over the 
first 4 months, decreasing to £127.51 between 8 and 12 months. Conversely, utility scores 
decreased with increased disability. The average EQ-5D utility score was 0.934 at 4 months 
for those with no disability, decreasing to 0.033 for those with complete disability. The 
average EQ-5D utility score for the whole sample increased from 0.587 immediately post-
injury to 0.817 at 12 months.  Relative costs and disutilities generated by the multivariate 
models are also presented by disability level and recovery trajectory. 
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Conclusions:  These results provide estimates of the costs and health state utilities associated 
with disability levels and recovery trajectories following acute whiplash injury. They can be 
used to inform estimates of the cost-effectiveness of interventions targeting whiplash 
associated disorders. 
 
Key Words: Whiplash, Outcome assessment, Health-related quality of life, Cost, Economic 
evaluation, Patient-reported outcome-measures 
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Introduction 
An acute whiplash injury (AWI) is a common soft-tissue injury often caused by motor 
vehicle collisions but also trips or falls resulting in a sudden jolt to the neck. The most 
common complaint following AWI is neck pain but people can also experience headaches, 
arm pain, tingling and numbness. The prevalence of whiplash associated disorders (WAD) is 
high and increasing worldwide, particularly within developed countries1. The incidence of 
WAD in the United Kingdom (UK) is estimated to be around 400,000 per year2, with an 
increase of 25% in whiplash claims between 2002 and 20082. Increases of a similar 
magnitude have also been reported in Germany3 and the Netherlands4, whilst Canada5, 
Australia6,7 and the USA8 all have annual incidences of over 100 per 100,000 people. 
Previous studies have documented the total societal burden of WAD, with an annual cost to 
the UK economy of over £3.1 billion in 2002, primarily made up of health service costs and 
productivity losses9. High societal costs have also been reported in the USA ($9 billion10) and 
Europe (€10 billion1). There is also evidence on long-term health consequences, with 30-50% 
of people suffering reduced health-related quality of life (HRQoL) caused by chronic 
symptoms associated with WAD11. However, these studies present group level results, not 
considering individual patient characteristics and how they interact with costs and HRQoL12. 
Evaluating the cost-effectiveness of possible interventions for WAD requires either 
prospectively collected patient-level data from a clinical trial/observational study, or the use 
of modelling techniques to simulate the costs and benefits of different interventions. These 
models often make use of estimates of patient-level costs and health utilities (preference-
based outcomes rooted in economic theory13) from secondary data sources, stratified by 
clinical and socio-demographic characteristics, which can be applied where prospective data 
are not collected. Currently there are no such reference values available for WAD, a problem 
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which this study addresses using prospectively collected data from the Managing Injuries of 
the Neck Trial (MINT)14. A regression modelling approach was used to estimate economic 
costs and HRQoL outcomes associated with severity of WAD and different recovery 
trajectories.  
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Materials and Methods 
MINT ran during 2005-2009 in 15 NHS emergency departments (EDs) in the UK14. A cluster 
randomised controlled trial; it recruited 3,851 individuals with WAD of grades I-III15. 
Centres were randomised to provide either active management (including The Whiplash 
Book16) or usual care. Then, patients whose symptoms persisted beyond 3 weeks and sought 
additional treatment were individually randomised to either a single or six physiotherapy 
sessions. 
Participants were sent questionnaires within three days of ED attendance, including the 
Short-Form Health Survey version 1 (SF-12)17 and the EQ-5D-3L18, which were used as 
baseline measurements. Postal questionnaire were sent at 4, 8 and 12 months post initial 
attendance, containing the SF-12 and EQ-5D, as well as the Neck Disability Index (NDI)19. 
Participants not responding within one week were sent a reminder letter, with those still not 
responding called over the telephone to obtain the core outcome measure set (NDI and EQ-
5D). 
Since this study’s focus was the economic costs and HRQoL outcomes associated with 
different disability levels and recovery trajectories, rather than evaluations of the 
effectiveness or cost-effectiveness of the interventions in the trial, all MINT participants were 
included in these analyses, regardless of trial allocation. 
Data collection instruments 
The NDI is a measure of neck pain related disability consisting of 10 questions measuring 
symptom severity and activity restriction, each scored from 0 (none) to 5 (severe). These are 
summed and doubled to give a total ranging from 0 to 100. Raw scores can be converted to a 
disability severity classification devised by Vernon et al, with scores of 8 or less 
corresponding to no disability, 10-28 mild disability, 30-48 moderate disability, 50-68 severe 
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disability and greater than 68 complete disability19. These categorisations are a commonly 
used approach in analyses using of the NDI20. Multiple longitudinal NDI measurements can 
be converted into a categorisation of patient recovery trajectories defined by Sterling et al, 
with injuries classed as mild, moderate or chronic-severe21. 
Participants completed resource use questionnaires at 4, 8 and 12 months, asking for details 
of all hospital inpatient, outpatient, and community healthcare and social services used, 
diagnostic tests undertaken and medications prescribed14. National unit costs (2009 prices, 
UK£) were applied to these data22, which were added to patient recorded expenditures on 
privately purchased healthcare to give total per patient societal costs14. 
MINT contained two measures of HRQoL, the SF-12 and EQ-5D. From the SF-12, a six 
dimension health-state classification called the SF-6D can be constructed, containing 
questions on physical functioning, role limitations, social functioning, pain, mental health and 
vitality23. The SF-6D describes 7,500 health states with utility values, calculated using the 
standard gamble technique from 611 members of the UK general population, ranging from 
0.345 to 1.024. 
The first five EQ-5D items form a health state classification system asking respondents to 
describe their mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
Responses to each of these are divided into three ordinal levels: (1) no problems; (2) 
some/moderate problems; (3) severe/extreme problems, generating a total of 243 possible 
health states. Utility scores can be produced using a UK specific tariff25, calculated from a 
time trade-off study of 3,336 people from the UK general population, taking values between -
0.594 and 1.0. Pre-injury utility values were not available for the MINT dataset and were 
therefore estimated from published general population health estimates, adjusted for age26. 
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Statistical Analysis 
Descriptive statistics were estimated for economic costs and health state utilities. Regression 
modelling was then used to estimate relationships between WAD severity and costs/health 
state utilities, adjusting for age, sex and pre-injury utility. In healthcare cost data, a significant 
proportion of individuals will often incur no costs and, for those that do, the distribution of 
costs is often highly skewed, with a small number of individuals incurring costs considerably 
higher than the mean27. A two-part model was thus used, the first a logistic regression model 
for the probability of incurring any costs. The second part was a generalised linear model 
(GLM) for costs incurred conditional on the cost being greater than zero. A log link function 
in the GLM means parameters have a multiplicative effect on cost, helping to model the 
skewed distribution of the data28. Models were produced for costs over the first four months 
of the follow-up period (with disability severity at 4 months as a predictor), and for costs 
between months 8 and 12 (using disability severity at 12 months). Since it was not possible to 
disentangle intervention costs from standard care, treatment allocation at initial 
randomisation was added as a covariate. 
Ordinary least squares (OLS) models for EQ-5D and SF-6D utility values (with injury 
severity, age, sex and pre-injury utility as covariates) were also produced. Utility scores at 4 
months (acute injury) and 12 months (chronic injury) were regressed on disability severity. 
However, such models allow for the prediction of values outside the range of the EQ-5D/SF-
6D. A high proportion of respondents also gave responses implying perfect health (a utility 
score of 1.0), something difficult to estimate using OLS models29. One solution is censored 
regression, which remove predictions outside the range and can lead to a cluster of 
predictions at the limit of the range30. However, these models assume that utility data are 
censored at 1.0 (i.e. higher values are possible, we simply cannot measure them) whereas in 
reality 1.0 is a genuine upper bound. Thus, we produced similar two-part models for utilities 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
as for cost data, with a logistic model for the probability of having a utility less than 1.0, 
followed by a GLM for total disutility, conditional on the utility score being less than 1.0. We 
did not include treatment allocation as a covariate, since any improvements in health from 
trial interventions should not affect the relationship between the different measures. 
To make use of the longitudinal data available, total costs (the sum of the three follow-up 
periods) and quality-adjusted life-years (QALYs) (estimated using the area under the EQ-5D 
utility curve, assuming linear interpolation between measurements) accumulated over the 
follow-up period were regressed on the Sterling trajectories defined above, including length 
of follow-up as a covariate to adjust for differential follow-up lengths between participants. 
The model for total costs was a two-part model, including treatment allocation as a covariate, 
whilst that for QALYs was an OLS model, as there are no longer fixed upper and lower 
bounds on this value. 
Statistical analyses were performed in R version 3.0.131. 
Sensitivity analysis 
Baseline analyses of costs used a societal perspective, including all cost items collected in the 
study. Sensitivity analyses were conducted, running the same models but restricting to NHS 
and personal social services (PSS) costs, the perspective recommended for economic 
evaluations in England by the National Institute for Health and Care Excellence22. 
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Results 
Descriptive statistics are presented in table 1. At baseline, using the Vernon classifications, 
29.4%, 42.0%, 20.8%, 6.5% and 1.3% of people with complete NDI data had no, mild, 
moderate, severe and complete neck-related disability, respectively. Baseline questionnaire 
response rates varied from 78.6% (SF-6D utility) to 89.1% (EQ-5D utility), whilst response 
rates at the end of the follow-up period ranged from 50.4%-69.2%. There were significant 
differences (at the 95% level) between responders and non-responders in age, sex, initial pain 
intensity and treatment group, with responders tending to be older (37.91 vs 36.65), more 
likely to be female (61% vs 53.4%), have a lower pain intensity at baseline (1.92 vs 1.78) and 
be randomised to the control group (44.9% vs 40.3%)32. However, there were no significant 
differences (again at the 5% level) in WAD grade at presentation, baseline EQ-5D utility, 
baseline SF-6D utility or costs between people who later went on to become responders or 
non-responders. 
Table 2 presents descriptive statistics for costs and health state utilities, stratified by NDI 
classification. NDI scores improve over time, with an increase from 29.4% to 48.5% of 
participants with no disability, with simultaneous decreases in the proportion of participants 
in other categories. There is also a consistent improvement in utility scores over time. This is 
driven by two distinct factors, the movement of people to less severe disability 
classifications, and an improvement in the average utility score reported by people with the 
same disability status. Both cost perspectives generated similar results, with more severe 
disability associated with higher costs (societal costs between baseline and 4 months 
averaged £99.55 for those with no disability compared to £668.53 for those with complete 
disability) and costs decreasing as time since injury increases (societal costs averaged 
£234.15 over the first 4 months, decreasing to £127.51 between 8 and 12 months). This 
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decline was more pronounced for NHS and PSS costs, which comprised 73.9% of total costs 
between baseline and 4 months, but only 51.8% between 8 and 12 months. 
Table 3 reports the two-part models for costs, where AIC-based model selection indicated the 
gamma family as the correct specification for the mean-variance relationship in the GLM. 
Increasing disability levels were monotonically associated with an increased probability of 
incurring costs, and an increase in the total cost given that one was incurred. Average societal 
costs, given one was incurred, were similar at 4 and 12 months (£166.67 vs. £174.40 for a 40 
year old woman in the intervention group with a baseline utility of 0.925 and no disability), 
but there was a considerably higher probability of incurring a cost during the first 4 months 
(0.564 vs. 0.195 for the same person as above). 
Table 4 presents the OLS regression models for utility scores. Disability levels were again 
highly significant predictors, with higher disability associated with lower utility scores (e.g. 
complete disability was associated with an EQ-5D decrement of 0.899 at 4 months and 0.888 
at 12 months compared to no disability). SF-6D scores were lower than EQ-5D scores for 
people with low levels of disability (0.856 vs. 0.948 at 4 months for the characteristics listed 
above), but considerably higher in people with higher levels of disability (0.543 vs. 0.039 for 
the same characteristics, but with complete disability). 
Table 5 summarises two-part models for the EQ-5D and SF-6D utility scores, respectively. 
Again, a gamma variance function was selected for the GLM, except for the 4 month SF-6D 
model, where a Gaussian distribution was selected using the AICs. Again, greater disability is 
associated with an increase in the probability of the utility score being less than 1.0, and the 
magnitude of that deviation, with the impact greater on probability than magnitude. There is 
also evidence of a difference in utility scores between men and women, though this is only 
present with the SF-6D. 
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Finally, table 6 reports models of total costs (with a gamma variance function in the GLM) 
and QALYs accrued over the follow-up period, using the Sterling trajectories as explanatory 
variables. For a woman with the characteristics listed above followed up for 1 year, both 
probability of cost and level of cost increase with more severe recovery trajectories (0.795 
and £353.76 for mild trajectory versus 0.986 and £633.10 for moderate and 0.989 and 
£1378.33 for chronic-severe, using societal costs), whilst number of QALYs decrease (0.790 
for mild versus 0.635 for moderate and 0.483 for chronic-severe).  
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Discussion 
This article reports economic costs, health state utilities and QALY profiles associated with 
differing disability levels during the recovery period following AWI. It uses a large dataset 
from a randomised controlled trial (MINT), which followed people through the recovery 
process14. The longitudinal dataset made it possible to consider costs and QALYs over the 
entire follow-up period, as well as at individual time points. Appropriate adjustments were 
made to address specific complexities that arise when using regression models on cost and 
HRQoL data. 
The results show the considerable impact neck-related disability can have, both on costs (a 20 
fold increase from the lowest to highest levels of disability) and health state utilities (an 
average drop of 0.9 in EQ-5D utility scores between those categories). Differences in cost 
captured the direct cost of managing the condition, indirect costs to the health system via the 
exacerbation of co-morbidities, and additional costs to the patients themselves. The 
sensitivity analyses, restricted to direct costs incurred by health and social care services, 
produced the same pattern of results. 
There are differences between this and similar studies in other clinical areas33,34. First, most 
such studies use clinically defined events or clinical severity measures as explanatory 
variables, whereas we use another patient-reported outcome measure (PROM), the NDI. This 
was driven by the prevalence of the NDI in trials of WAD23, but presents both advantages 
and disadvantages. There is growing acceptance of the importance of PROMs in trials, and of 
their usefulness as a robust way of reflecting patient perspectives35,36. However, the reliance 
on patient completion leads to higher levels of missing data, which can both bias analyses and 
lead to difficulties in generalisation. One might expect participants in worse health to be less 
likely to return questionnaires, resulting in utilities appearing higher than is accurate, and 
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costs lower. However, there were no significant differences in our outcomes variables (EQ-
5D utility, SF-6D utility, costs) between patients who went on to become responders and non-
responders. 
Secondly, whilst two-part models are now accepted as a technique for modelling of cost data, 
their use for utilities has been less common. Nevertheless, it has been recognised both that a 
significant proportion of participants will be in a state of “full health” at any time point, and 
that changes in mean utility scores for a population can be significantly driven by the move 
towards/away from the “full health” state37. This effect is particularly noticeable with the EQ-
5D, due to the large gap between the (11111) state (responding 1 to every question, the best 
possible health state) and that with the next highest utility score38. Thus two-part models, 
which explicitly accommodate the switch from “full health” to other states, are equally useful 
in dealing with health utilities as costs. Other, more complex regression methods such as beta 
regression have also been proposed, but there is little evidence that they lead to 
improvements in model fit39. 
Thirdly, all the usual caveats concerning data from clinical trials also apply in this context40. 
The study inclusion criteria mean the population may not be fully representative of the 
background population of WAD patients. However, since MINT was an extremely pragmatic 
trial, designed to reflect routine care as closely as possible, this should not be as significant a 
problem as with less representative trials. Finally, difference in healthcare practices and 
preference structures mean that the patterns of resource use (and thus cost), compensation 
payments and health utilities can vary considerably between different countries41. Thus, 
careful thought should be given to the necessary assumptions when applying these results to 
contexts outside of the UK healthcare system.  
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When considering correlations between initial disability and long term costs, it is important to 
note that the biological severity of the initial injury may not be the only cause. Other 
literature has suggested that patients may ascribe pre-existing or unrelated symptoms as being 
the effects of whiplash, thereby overestimating the impact of the event42. Further, there have 
long been concerns about the difficulties in defining injury mechanisms and disease 
categories in WAD, and the nature of the link between biological injury, high initial 
symptoms and long-term prognosis (e.g. patients with compensation claims and lawsuits have 
significantly worse long-term outcomes than those without, even when adjusting for initial 
severtity42). However, since we have no reason to believe these effects would be greater in 
one arm of the trial than the other, they are unlikely to bias results derived from within trial 
comparisons. 
Nevertheless, despite these limitations, this research should prove useful to both economists 
and health service researchers, by providing estimates of economic costs and preference-
based HRQoL outcomes associated with different disability levels and recovery trajectories 
following AWI. These estimates can be used as inputs when modelling the cost-effectiveness 
of interventions for the management of WAD, and the budgetary impact of those 
interventions. 
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Table 1 ‐ Baseline characteristics of the MINT study population 
Variable  N (%) 
Sex (male)  1661/3851 (43.1%) 
Sex (female)  2133/3851 (55.4%) 
Treatment group step 1 (usual care)  1598/3851 (41.5%) 
Treatment group step 1 (active management)  2253/3851 (58.5%) 
Treatment group step 2* (advice)  287/574 (50%) 
Treatment group step 2* (physiotherapy)  287/574 (50%) 
WAD grade at presentation (grade 1)  2088/3851 (54.2%) 
WAD grade at presentation (grade 2)  1659/3851 (43.1%) 
WAD grade at presentation (grade 3)  104/3851 (2.7%) 
  Mean (SD) 
Initial pain intensity  5.13 (1.89) 
EQ‐5D utility score ‐ baseline  0.587 (0.298) 
SF‐6D utility score – baseline  0.647 (0.136) 
NDI score – 4 months  21.03 (17.45) 
Percentages may not add up to 100% due to missing data. *The denominators are lower here as not 
all participants were randomised at step 2. SD: standard deviation. WAD: Whiplash associated 
disorder.   
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Table 2 – Descriptive statistics (Vernon categories, utility scores and costs over time, stratified by 
disability status) 
Percentage of participants in each Vernon category by time point 
Vernon category  Baseline  4 months  8 months  12 months 
No disability  N/A  29.4  42.5  48.5 
Mild disability  N/A  42.0  38.1  34.4 
Moderate disability  N/A  20.8  14.1  12.9 
Severe disability  N/A  6.5  4.2  3.3 
Complete disability  N/A  1.3  1.0  0.9 
 
Mean (SD) EQ‐5D utility scores at each time point, stratified by Vernon category at 4 months 
Vernon category  Baseline  4 months  8 months  12 months 
No disability  0.766 (0.210)  0.934 (0.128)  0.936 (0.131)  0.944 (0.127) 
Mild disability  0.613 (0.232)  0.760 (0.141)  0.818 (0.171)  0.844 (0.177) 
Moderate disability  0.463 (0.303)  0.612 (0.189)  0.671 (0.227)  0.699 (0.235) 
Severe disability  0.226 (0.335)  0.327 (0.305)  0.465 (0.315)  0.534 (0.317) 
Complete disability  0.080 (0.308)  0.033 (0.291)  0.109 (0.306)  0.213 (0.299) 
All  0.587 (0.298)  0.739 (0.246)  0.792 (0.241)  0.817 (0.233) 
 
Mean (SD) SF‐6D utility scores at each time point, stratified by Vernon category at 4 months 
Vernon category  Baseline  4 months  8 months  12 months 
No disability  0.735 (0.142)  0.858 (0.100)  0.868 (0.100)  0.873 (0.096) 
Mild disability  0.634 (0.122)  0.766 (0.115)  0.800 (0.124)  0.809 (0.122) 
Moderate disability  0.569 (0.086)  0.637 (0.100)  0.702 (0.126)  0.714 (0.131) 
Severe disability  0.547 (0.076)  0.546 (0.076)  0.599 (0.118)  0.646 (0.120) 
Complete disability  0.531 (0.069)  0.508 (0.054)  0.525 (0.080)  0.548 (0.079) 
All  0.647 (0.136)  0.752 (0.142)  0.878 (0.140)  0.800 (0.135) 
 
Mean (SD) societal costs at each time point, stratified by Vernon category at 4 months* 
Vernon category  Baseline  4 months  8 months  12 months 
No disability  N/A  £99.55 (198.55)  £31.15 (121.27)  £23.02 (118.78) 
Mild disability  N/A  £223.01 (305.64)  £80.95 (175.05)  £66.36 (360.83) 
Moderate disability  N/A  £325.39 (340.50)  £236.64 (602.12)  £155.64 (276.18) 
Severe disability  N/A  £535.89 (785.54)  £472.53 (1011.83)  £810.31 (5435.70)
Complete disability  N/A  £668.53 (352.73)  £412.94 (329.17)  £601.58 (853.23) 
All  N/A  £234.15 (365.47)  £131.93 (420.74)  £127.51 (1292.73)
 
Mean (SD) health and social care costs at each time point, stratified by Vernon category at 4 months* 
Vernon category  Baseline  4 months  8 months  12 months 
No disability  N/A  £72.49 (141.42)  £17.42 (93.05)  £12.33 (82.03) 
Mild disability  N/A  £159.64 (228.34)  £47.27 (128.81)  £31.93 (113.73) 
Moderate disability  N/A  £254.22 (269.74)  £140.64 (246.24)  £100.29 (197.41) 
Severe disability  N/A  £376.31 (406.29)  £331.02 (613.89)  £294.06 (774.77) 
Complete disability  N/A  £534.34 (395.78)  £340.49 (284.25)  £363.37 (506.64) 
All  N/A  £172.96 (254.23)  £81.74 (230.90)  £66.08 (262.15) 
*Costs at a time point refer to those accumulated over the 4 months prior.   
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Table 3 – Two‐part models for societal and NHS cost data, modelling probability of cost for an 
individual being greater than 0, and total cost given that cost is greater than 0 
All costs 
  Model 1 (4 months)  Model 2 (12 months) 
  Probability of cost  Total cost given cost 
>0 
Probability of cost  Total cost given 
cost >0 
Intercept†  0.243* (0.112)  5.167*** (0.070)  ‐1.614*** (0.111)  4.925*** (0.196) 
Sex (female)  ‐0.099 (0.110)  ‐0.047 (0.053)  0.119 (0.100)  0.050 (0.141) 
Age  ‐0.014 (0.011)  ‐0.004 (0.005)  0.001 (0.010)  0.020 (0.013) 
Baseline utility  0.045 (3.178)  ‐0.280 (1.502)  3.089 (2.843)  6.654 (3.847) 
Treatment group  0.170 (0.108)  0.019 (0.052)  ‐0.001 (0.099)  ‐0.060 (0.138) 
Mild disability  1.753*** (0.117)  0.382*** (0.068)  2.219*** (0.104)  0.080 (0.187) 
Moderate disability  2.742*** (0.207)  0.701*** (0.078)  3.860*** (0.206)  0.642** (0.311) 
Severe disability  3.586*** (0.512)  1.185*** (0.109)  4.391*** (0.469)  1.510*** (0.311) 
Complete disability  16.40 (387.97)  1.388*** (0.207)  4.750*** (1.025)  3.280*** (0.518) 
Sample size  2760  2243  2601  1218 
 
National health service and personal social services costs only 
  Model 1 (4 months)  Model 2 (12 months) 
  Probability of cost  Total cost given cost 
>0 
Probability of cost  Total cost given 
cost >0 
Intercept†  ‐0.317** (0.101)  5.148*** (0.066)  ‐2.669*** (0.142)  5.395*** (0.173) 
Sex (female)  ‐0.068 (0.090)  ‐0.058 (0.048)  ‐0.023 (0.109)  0.025 (0.111) 
Age  ‐0.015 (0.009)  ‐0.002 (0.005)  0.009 (0.010)  ‐0.006 (0.011) 
Baseline utility  ‐1.021 (2.578)  0.583 (1.359)  3.915 (2.987)  ‐0.139 (2.982) 
Treatment group  0.085 (0.089)  0.019 (0.048)  0.157 (0.107)  0.054 (0.109) 
Mild disability  1.183*** (0.097)  0.296*** (0.065)  1.807*** (0.132)  ‐0.396* (0.169) 
Moderate disability  2.142*** (0.141)  0.588*** (0.072)  3.220*** (0.162)  0.065 (0.177) 
Severe disability  3.013*** (0.309)  0.906*** (0.096)  4.245*** (0.315)  0.771*** (0.226) 
Complete disability  15.97 (235.39)  1.195*** (0.173)  5.763*** (1.028)  1.303*** (0.325) 
Sample size  2760  1853  2601  681 
*p value <0.05, **p value <0.01, ***p value <0.001. ϮThe reference case is a man, 36 years of age, 
receiving standard care, with a pre‐injury utility of 0.9 and no neck‐related disability. 
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Table 4 – Ordinary least squares models for EQ‐5D and SF‐6D health state utilities at 4 and 12 
months post baseline 
  EQ‐5D (4 months)  SF‐6D (4 months)  EQ‐5D (12 months)  SF‐6D (12 months) 
Intercept†  0.933*** (0.007)  0.863*** (0.005)  0.951*** (0.006)  0.887*** (0.004) 
Sex (female)  0.001 (0.006)  ‐0.008 (0.004)  ‐0.004 (0.006)  ‐0.023*** (0.005) 
Age  0.0003 (0.001)  0.0002 (0.0004)  ‐0.002*** (0.001)  ‐0.0005 (0.0005) 
Baseline utility  0.178 (0.180)  0.035 (0.128)  ‐0.353 (0.183)  ‐0.037 (0.133) 
Mild disability  ‐0.175*** (0.007)  ‐0.093*** (0.005)  ‐0.165*** (0.007)  ‐0.094*** (0.005) 
Moderate disability  ‐0.322*** (0.009)  ‐0.222*** (0.006)  ‐0.332*** (0.010)  ‐0.223*** (0.007) 
Severe disability  ‐0.614*** (0.014)  ‐0.313*** (0.010)  ‐0.598*** (0.018)  ‐0.321*** (0.014) 
Complete disability  ‐0.899*** (0.028)  ‐0.350*** (0.022)  ‐0.888*** (0.033)  ‐0.318*** (0.028) 
Sample size  2899  2366  2584  1925 
*p value <0.05, **p value <0.01, ***p value <0.001. ϮThe reference case is a man, 36 years of age, 
with a pre‐injury utility of 0.9 and no neck‐related disability.   
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Table 5 – Two‐part models for EQ‐5D and SF‐6D health state utilities, modelling probability that the 
utility of an individual is less than 1, and total disutility given the utility is less than 1 
EQ‐5D models 
  Model 1 (4 months)  Model 2 (12 months) 
  Probability of 
disutility 
Disutility given 
utility < 1 
Probability of 
disutility 
Disutility given 
utility < 1 
Intercept†  ‐0.924*** (0.099)  ‐1.494*** (0.032)  ‐1.392*** (0.093)  ‐1.460*** (0.037) 
Sex (female)  0.040 (0.116)  0.001 (0.021)  0.202 (0.108)  ‐0.013 (0.030) 
Age  0.016 (0.012)  ‐0.002 (0.002)  0.034** (0.011)  0.004 (0.003) 
Baseline utility  2.619 (3.483)  ‐0.966 (0.575)  2.204 (3.074)  0.982 (0.775) 
Mild disability  2.890*** (0.116)  0.197*** (0.033)  2.625*** (0.110)  0.167*** (0.038) 
Moderate disability  5.642*** (0.456)  0.556*** (0.035)  4.629*** (0.329)  0.550*** (0.044) 
Severe disability  18.425 (291.349)  1.108*** (0.045)  18.668 (425.340)  1.038*** (0.067) 
Complete disability  18.405 (641.121)  1.455*** (0.081)  18.703 (795.660)  1.403*** (0.114) 
Sample size  2899  2144  2584  1423 
 
SF‐6D models 
  Model 1 (4 months)  Model 2 (12 months) 
  Probability of 
disutility 
Disutility given 
utility < 1 
Probability of 
disutility 
Disutility given 
utility < 1 
Intercept†  1.811*** (0.159)  ‐1.846*** (0.027)  1.422*** (0.127)  ‐1.965*** (0.023) 
Sex (female)  0.647** (0.229)  0.015 (0.016)  0.847*** (0.186)  0.089*** (0.025) 
Age  0.040 (0.025)  ‐0.0004 (0.002)  0.027 (0.019)  ‐00.002 (0.002) 
Baseline utility  5.266 (7.579)  0.028 (0.452)  ‐1.657 (6.084)  ‐0.496 (0.678) 
Mild disability  2.466*** (0.340)  0.398*** (0.029)  2.354*** (0.350)  0.427*** (0.027) 
Moderate disability  18.320 (810.372)  0.827*** (0.029)  17.502 (672.306)  0.873*** (0.037) 
Severe disability  18.341 (1537.141)  1.051*** (0.032)  17.548 (1449.526)  1.115*** (0.072) 
Complete disability  18.300 (3576.154)  1.132*** (0.050)  17.588 (1906.713)  1.113*** (0.141) 
Sample size  2366  2277  1925  1779 
*p value <0.05, **p value <0.01, ***p value <0.001. ϮThe reference case is a man, 36 years of age, 
with a pre‐injury utility of 0.9 and no neck‐related disability. 
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Table 6 – Two‐part model for costs and quality‐adjusted life‐years (calculated from the EQ‐5D) over 
full follow‐up period 
Societal costs 
  Probability of cost  Total cost given cost >0 
Intercept†  1.087*** (0.130)  5.825*** (0.107) 
Sex (female)  0.001 (0.125)  0.001 (0.096) 
Age  ‐0.001 (0.012)  0.001 (0.009) 
Baseline utility  ‐1.235 (3.648)  1.345 (2.688) 
Treatment group  0.302* (0.123)  0.005 (0.095) 
Trajectory (moderate)  2.933*** (0.508)  0.582*** (0.133) 
Trajectory (chronic‐severe)  3.157*** (0.508)  1.360*** (0.124) 
Length of follow‐up (days)  0.004 (0.002)  ‐0.002 (0.001) 
Sample size  2265  1928 
 
National Health Service and personal social services costs 
  Probability of cost  Total cost given cost >0 
Intercept†  0.255* (0.106)  5.629*** (0.075) 
Sex (female)  0.112 (0.100)  ‐0.013 (0.067) 
Age  ‐0.010 (0.010)  ‐0.003 (0.006) 
Baseline utility  ‐2.075 (2.877)  0.301 (1.828) 
Treatment group  0.234* (0.099)  0.040 (0.066) 
Trajectory (moderate)  1.783*** (0.206)  0.568*** (0.089) 
Trajectory (chronic‐severe)  2.500*** (0.249)  1.090*** (0.082) 
Length of follow‐up (days)  0.002 (0.002)  ‐0.002 (0.001) 
Sample size  2265  1614 
 
Quality‐adjusted life‐years 
  Parameters 
Intercept†  0.802*** (0.006) 
Sex (female)  ‐0.013* (0.006) 
Age  ‐0.001* (0.001) 
Baseline utility  0.055 (0.170) 
Trajectory (moderate)  ‐0.155*** (0.009) 
Trajectory (chronic‐severe)  ‐0.307*** (0.008) 
Length of follow‐up  0.002*** (0.0001) 
Sample size  2256 
*p value <0.05, **p value <0.01, ***p value <0.001. ϮThe reference case is a man, 36 years of age, 
receiving standard care, with a pre‐injury utility of 0.9, following a mild recovery trajectory and being 
followed up for one year. 
 
